Nothing said here yet.
to join the conversation.
Sanofi (NASDAQ:SNY) reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases.
SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.
Investing.com -- Regeneron Pharmaceutical (NASDAQ:REGN)s shares rose 4% in premarket trading on Friday after the drugmaker reported third-quarter profit and revenue far above Wall Street estimates, driven mainly by a surge in payments from partner Sanofi on…
Investing.com-- Sanofi SA (EPA:SASY) clocked stronger-than-expected third-quarter earnings on Friday, aided chiefly by robust sales of its eczema drug Dupixent, with the French drugmaker also hiking its annual outlook.
Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
Sanofi Canada is pleased to announce that Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will be available in all 10 provinces and the Yukon for the 2026-2027 season through provincial respiratory programs and most private insurers.
Analysts say that duvakitug could be differentiated from other pipeline TL1A candidates as the race to market heats up.
ScionxBio will direct optimisation programmes through to in vivo validation.
Teva Pharmaceutical Industries' (TEVA) affiliate Teva Pharmaceuticals and Sanofi (SNY) said Tuesday
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44Duvakitug was well…
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial updates and Sanofi optioning a development candidate that triggered a US$10 million milestone within a broader US$144 million received…